Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial
Go back to Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial| Regeneron (NASDAQ: REGN) | Delayed: 623.43 +5.40 (0.87%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $618.03 | 52 Week High | $592.36 | |||
| Open | $621.63 | 52 Week Low | $325.35 | |||
| Day High | $631.18 | P/E | 163.63 | |||
| Day Low | $619.27 | EPS | $3.81 | |||
| Volume | 839,787 | |||||
| Regeneron (NASDAQ: REGN) | Delayed: 623.43 +5.40 (0.87%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $618.03 | 52 Week High | $592.36 | |||
| Open | $621.63 | 52 Week Low | $325.35 | |||
| Day High | $631.18 | P/E | 163.63 | |||
| Day Low | $619.27 | EPS | $3.81 | |||
| Volume | 839,787 | |||||

